|
|
| PMID |
|
|
| TITLE |
|
| Discontinuation of antidepressant treatment: a retrospective cohort study on more than 20,000 participants. |
|
| ABSTRACT |
|
| BACKGROUND |
NlmCategory: BACKGROUND |
| Factors influencing antidepressant treatment discontinuation are poorly understood. In the present study, we aimed to estimate the prevalence of antidepressant treatment discontinuation and identify demographic characteristics, psychiatric comorbidities, and specific side effects associated with treatment discontinuation. |
| METHODS |
NlmCategory: METHODS |
| Factors influencing antidepressant treatment discontinuation are poorly understood. In the present study, we aimed to estimate the prevalence of antidepressant treatment discontinuation and identify demographic characteristics, psychiatric comorbidities, and specific side effects associated with treatment discontinuation. We leveraged data from the Australian Genetics of Depression Study (AGDS; N = 20,941) to perform a retrospective cohort study on antidepressant treatment discontinuation. Participants were eligible if they were over 18 years of age, had taken antidepressants in the past 4 years, and provided informed consent. |
| RESULTS |
NlmCategory: RESULTS |
| Factors influencing antidepressant treatment discontinuation are poorly understood. In the present study, we aimed to estimate the prevalence of antidepressant treatment discontinuation and identify demographic characteristics, psychiatric comorbidities, and specific side effects associated with treatment discontinuation. We leveraged data from the Australian Genetics of Depression Study (AGDS; N = 20,941) to perform a retrospective cohort study on antidepressant treatment discontinuation. Participants were eligible if they were over 18 years of age, had taken antidepressants in the past 4 years, and provided informed consent. Among the ten antidepressants studied, the highest discontinuation rates were observed for Mirtazapine (57.3%) and Amitriptyline (51.6%). Discontinuation rates were comparable across sexes except for Mirtazapine, for which women were more likely to discontinue. The two most common side effects, reduced sexual function and weight gain, were not associated with increased odds of treatment discontinuation. Anxiety, agitation, suicidal thoughts, vomiting, and rashes were associated with higher odds for treatment discontinuation, as were lifetime diagnoses of PTSD, ADHD, and a higher neuroticism score. Educational attainment showed a negative (protective) association with discontinuation across medications. |
| CONCLUSIONS |
NlmCategory: CONCLUSIONS |
| Factors influencing antidepressant treatment discontinuation are poorly understood. In the present study, we aimed to estimate the prevalence of antidepressant treatment discontinuation and identify demographic characteristics, psychiatric comorbidities, and specific side effects associated with treatment discontinuation. We leveraged data from the Australian Genetics of Depression Study (AGDS; N = 20,941) to perform a retrospective cohort study on antidepressant treatment discontinuation. Participants were eligible if they were over 18 years of age, had taken antidepressants in the past 4 years, and provided informed consent. Among the ten antidepressants studied, the highest discontinuation rates were observed for Mirtazapine (57.3%) and Amitriptyline (51.6%). Discontinuation rates were comparable across sexes except for Mirtazapine, for which women were more likely to discontinue. The two most common side effects, reduced sexual function and weight gain, were not associated with increased odds of treatment discontinuation. Anxiety, agitation, suicidal thoughts, vomiting, and rashes were associated with higher odds for treatment discontinuation, as were lifetime diagnoses of PTSD, ADHD, and a higher neuroticism score. Educational attainment showed a negative (protective) association with discontinuation across medications. Our study suggests that not all side effects contribute equally to discontinuation. Common side effects such as reduced sexual function and weight gain may not necessarily increase the risk of treatment discontinuation. Side effects linked to discontinuation can be divided into two groups, psychopathology related and allergy/intolerance. |
| © 2023. The Author(s). |
|
| DATE PUBLISHED |
|
|
| HISTORY |
|
| PUBSTATUS |
PUBSTATUSDATE |
| received |
2023/05/15 |
| accepted |
2023/11/13 |
| medline |
2023/11/25 12:43 |
| pubmed |
2023/11/25 12:42 |
| entrez |
2023/11/24 23:51 |
|
| AUTHORS |
|
| NAME |
COLLECTIVENAME |
LASTNAME |
FORENAME |
INITIALS |
AFFILIATION |
AFFILIATIONINFO |
| Garcia-Marin LM |
|
Garcia-Marin |
Luis M |
LM |
|
School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. luis.garciamarin@qimrberghofer.edu.au. |
| Mulcahy A |
|
Mulcahy |
Aoibhe |
A |
|
School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. |
| Byrne EM |
|
Byrne |
Enda M |
EM |
|
Child Health Research Centre, The University of Queensland, Brisbane, QLD, Australia. |
| Medland SE |
|
Medland |
Sarah E |
SE |
|
Mental Health & Neuroscience Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. |
| Wray NR |
|
Wray |
Naomi R |
NR |
|
Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia. |
| Chafota F |
|
Chafota |
Freddy |
F |
|
Mental Health & Neuroscience Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. |
| Lind PA |
|
Lind |
Penelope A |
PA |
|
School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. |
| Martin NG |
|
Martin |
Nicholas G |
NG |
|
Mental Health & Neuroscience Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. |
| Hickie IB |
|
Hickie |
Ian B |
IB |
|
Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia. |
| Rentería ME |
|
Rentería |
Miguel E |
ME |
|
School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. |
| Campos AI |
|
Campos |
Adrian I |
AI |
|
Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia. |
|
| INVESTIGATORS |
|
|
| JOURNAL |
|
| VOLUME: 22 |
| ISSUE: 1 |
| TITLE: Annals of general psychiatry |
| ISOABBREVIATION: Ann Gen Psychiatry |
| YEAR: 2023 |
| MONTH: Nov |
| DAY: 24 |
| MEDLINEDATE: |
| SEASON: |
| CITEDMEDIUM: Print |
| ISSN: 1744-859X |
| ISSNTYPE: Print |
|
| MEDLINE JOURNAL |
|
| MEDLINETA: Ann Gen Psychiatry |
| COUNTRY: England |
| ISSNLINKING: 1744-859X |
| NLMUNIQUEID: 101236515 |
|
| PUBLICATION TYPE |
|
| PUBLICATIONTYPE TEXT |
| Journal Article |
|
| COMMENTS AND CORRECTIONS |
|
|
| GRANTS |
|
|
| GENERAL NOTE |
|
|
| KEYWORDS |
|
| KEYWORD |
| Antidepressant treatment |
| Comorbidities |
| Discontinuation |
| SNRI |
| SSRI |
| Side effects |
|
| MESH HEADINGS |
|
|
| SUPPLEMENTARY MESH |
|
|
| GENE SYMBOLS |
|
|
| CHEMICALS |
|
|
| OTHER ID's |
|
|
|
